physostigmine has been researched along with Colorectal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beilin, B; Binder, Y; Chervinsky, A; Melzer, E; Smolyarenko, V; Yardeni, IZ; Zeidel, A | 1 |
| Blandizzi, C; Colucci, R; Danesi, R; De Paolis, B; Del Tacca, M; Di Paolo, A; Falcone, A | 1 |
1 trial(s) available for physostigmine and Colorectal Neoplasms
| Article | Year |
|---|---|
Combining physostigmine with meperidine for sedation and analgesia during colonoscopy.
Topics: Adult; Aged; Ambulatory Care; Analgesia; Analysis of Variance; Colonoscopy; Colorectal Neoplasms; Conscious Sedation; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Mass Screening; Meperidine; Middle Aged; Pain Measurement; Patient Satisfaction; Physostigmine; Probability; Risk Factors; Sensitivity and Specificity | 2005 |
1 other study(ies) available for physostigmine and Colorectal Neoplasms
| Article | Year |
|---|---|
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Cholinesterase Inhibitors; Colorectal Neoplasms; Confidence Intervals; Female; Humans; Irinotecan; Male; Middle Aged; Physostigmine | 2002 |